Literature DB >> 6128217

Adverse effects of drugs on muscle.

F L Mastaglia.   

Abstract

A variety of drugs used in clinical practice may cause myopathy or interfere with neuromuscular transmission. The precise incidence of such disorders is not known, but it is almost certainly higher than is generally suspected. An important aspect of drug-induced muscular disorders is their reversibility if the offending agent is withdrawn, whereas failure to do so may lead to unnecessary morbidity. The study of drug effects on muscle provides a means of investigating the pathological reactions of muscle, and of producing experimental models of naturally occurring myopathies. Drug-induced myopathies may result from a direct toxic effect, which may be local when the drug is injected into a muscle or more diffuse when the drug is taken systemically, or may be secondary to electrolyte disturbances, muscle compression, ischaemia, neural activation or to the development of an immunological reaction directed against muscle. Repeated injections of antibiotics or drugs of addiction may lead to severe muscle fibrosis and contractures. A variety of drugs may cause an acute or subacute painful necrotising myopathy which may be associated with myoglobinuria, at times leading to acute renal failure. Clofibrate and epsilon aminocaproic acid are the drugs most frequently implicated, but a similar syndrome may occur in alcoholics and heroin addicts. Certain hypocholesterolaemic agents may induce myotonia by altering the sterol composition of the muscle cell membrane, while certain drugs including beta-adrenergic blockers and agonists, succinylcholine and diuretics may exacerbate or unmask pre-existing myotonia. In the syndrome of malignant hyperpyrexia, halothane, succinylcholine and various other agents may induce a potentially fatal state of muscular rigidity and hypermetabolism in susceptible individuals as a result of a defect in the calcium transport function of the sarcoplasmic reticulum and possibly of other cellular membranes. In corticosteroid myopathy, which is the most common form of drug-induced myopathy, there is selective atrophy of type 2 muscle fibres and the primary metabolic effect is an inhibition of RNA and protein synthesis, although protein degradation is also increased. Chloroquine and a number of related drugs with amphiphilic cationic properties may induce lysosomal storage myopathy, which may be associated with cardiomyopathy and with a more widespread form of lipidosis.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6128217     DOI: 10.2165/00003495-198224040-00003

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  135 in total

1.  THE RATE OF RECOVERY OF REVERSIBLE MYOPATHIES AND THE EFFECTS OF ANABOLIC AGENTS IN STEROID MYOPATHY.

Authors:  E N COOMES
Journal:  Neurology       Date:  1965-06       Impact factor: 9.910

2.  Letter: Myasthenic syndrome during treatment with practolol.

Authors:  R O Hughes; F J Zacharias
Journal:  Br Med J       Date:  1976-02-21

3.  Dysfunction of sarcoplasmic reticulum in rabbit and human steroid myopathy.

Authors:  S Shoji; A Takagi; H Sugita; Y Toyokura
Journal:  Exp Neurol       Date:  1976-05       Impact factor: 5.330

4.  Steroid myopathy. A study of the evolution of the muscle lesion in rabbits.

Authors:  A K Afifi; R A Bergman
Journal:  Johns Hopkins Med J       Date:  1969-02

5.  Corticosteroid myopathy.

Authors:  E N Coomes
Journal:  Ann Rheum Dis       Date:  1965-09       Impact factor: 19.103

6.  The effect of amphetamines on culture myotubes: selective inhibition of protein synthesis.

Authors:  R Salomon
Journal:  Life Sci       Date:  1978-11-09       Impact factor: 5.037

7.  Muscle and nerve changes induced by perhexiline maleate in man and mice.

Authors:  M Fardeau; F M Tomé; P Simon
Journal:  Muscle Nerve       Date:  1979 Jan-Feb       Impact factor: 3.217

8.  Rationale for dantrolene vs. procainamide for treatment of malignant hyperthermia.

Authors:  T E Nelson; E H Flewellen
Journal:  Anesthesiology       Date:  1979-02       Impact factor: 7.892

9.  Myopathy due to epsilon amino-caproic acid.

Authors:  C Kennard; M Swash; R A Henson
Journal:  Muscle Nerve       Date:  1980 May-Jun       Impact factor: 3.217

10.  Agonist-induced myopathy at the neuromuscular junction is mediated by calcium.

Authors:  J P Leonard; M M Salpeter
Journal:  J Cell Biol       Date:  1979-09       Impact factor: 10.539

View more
  6 in total

1.  Impact of physical training on the ultrastructure of midthigh muscle in normal subjects and in patients treated with glucocorticoids.

Authors:  F F Horber; H Hoopeler; J R Scheidegger; B E Grünig; H Howald; F J Frey
Journal:  J Clin Invest       Date:  1987-04       Impact factor: 14.808

2.  Fibrous myopathy as a complication of repeated intramuscular injections for chronic headache.

Authors:  R Burnham; S McNeil; C Hegedus; D S Gray
Journal:  Pain Res Manag       Date:  2006       Impact factor: 3.037

3.  Evaluation of laryngeal findings in users of inhaled steroids.

Authors:  Gul Ozbilen Acar; Nurten Uzun Adatepe; Asim Kaytaz; Deniz Tuna Edizer; Bilun Gemicioglu; Cengiz Yagiz; Ahmet Dirican
Journal:  Eur Arch Otorhinolaryngol       Date:  2009-11-12       Impact factor: 2.503

4.  Glucocorticoids counteract hypertrophic effects of myostatin inhibition in dystrophic muscle.

Authors:  David W Hammers; Cora C Hart; Andreas Patsalos; Michael K Matheny; Lillian A Wright; Laszlo Nagy; H Lee Sweeney
Journal:  JCI Insight       Date:  2020-01-16

5.  Acute myopathy associated with large parenteral dose of corticosteroid in myasthenia gravis.

Authors:  P K Panegyres; M Squier; K R Mills; J Newsom-Davis
Journal:  J Neurol Neurosurg Psychiatry       Date:  1993-06       Impact factor: 10.154

6.  Artemisinin-Based Combination Therapy Synergized with Medicinal Plants to Induce Musculotoxic Effects.

Authors:  Thérèse Daubrey-Potey; Valéry Adjogoua; Mamadou Kamagaté; Serges Aoussi; Mireille Dosso
Journal:  Evid Based Complement Alternat Med       Date:  2021-07-08       Impact factor: 2.629

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.